Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA–IsdB–Hlg as a vaccine candidate

Medical Microbiology and Immunology

Volumn 205, Issue 1, 2016, Pages 47-55

  Delfani, Somayeh ^a   Mohabati Mobarez, Ashraf ^a   Imani Fooladi, Abbas Ali ^b   Amani, Jafar ^b   Emaneini, Mohammad ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clumping factor A (ClfA); Gamma hemolysin B (HlgB) recombinant protein; Immunogenicity; Iron surface determinant B (IsdB); Staphylococcus aureus

Indexed keywords

BACTERIAL VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MESSENGER RNA; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN CLUMPING FACTOR A IRON SURFACE DETERMINANT B GAMMA HEMOLYSIN B; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIAL TOXIN; CATION TRANSPORT PROTEIN; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULASE; GAMMA-HEMOLYSIN, STAPHYLOCOCCUS AUREUS; HEMOLYSIN; HYBRID PROTEIN; ISDB PROTEIN, STAPHYLOCOCCUS AUREUS; RECOMBINANT VACCINE; STAPHYLOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL CELL; BACTERIAL LOAD; BAGG ALBINO MOUSE; BIOINFORMATICS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; INFECTION PREVENTION; MACROPHAGE; MORTALITY RATE; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; SPLEEN; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS;

ANIMALS; BACTERIAL LOAD; BACTERIAL PROTEINS; BACTERIAL TOXINS; CATION TRANSPORT PROTEINS; COAGULASE; DISEASE MODELS, ANIMAL; FEMALE; HEMOLYSIN PROTEINS; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84955411873     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-015-0425-y     Document Type: Article

References (40)

1. Archer GL (1998) Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 26(5):1179–1181
2. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339(8):520–532. doi:10.1056/NEJM199808203390806
3. Wertheim HF, Vos MC, Ott A, Voss A, Kluytmans JA, Vandenbroucke-Grauls CM, Meester MH, van Keulen PH, Verbrugh HA (2004) Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 140(6):419–425
4. David MZ, Daum RS (2010) Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23(3):616–687. doi:10.1128/CMR.00081-09
5. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis 13(12):1840–1846. doi:10.3201/eid1312.070629
6. Spellberg B, Daum R (2012) Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 34(2):335–348. doi:10.1007/s00281-011-0293-5
7. Schaffer AC, Lee JC (2008) Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 32(Suppl 1):S71–S78. doi:10.1016/j.ijantimicag.2008.06.009
8. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O’Neill G, Day NP (2002) Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 70(9):4987–4996
9. Josefsson E, Higgins J, Foster TJ, Tarkowski A (2008) Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 3(5):e2206. doi:10.1371/journal.pone.0002206
10. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM (2003) Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71(12):6864–6870
11. Hartford OM, Wann ER, Hook M, Foster TJ (2001) Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding. J Biol Chem 276(4):2466–2473. doi:10.1074/jbc.M007979200
12. Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB (2012) Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One 7(10):e46648. doi:10.1371/journal.pone.0046648
13. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74(4):2215–2223. doi:10.1128/IAI.74.4.2215-2223.2006
14. Mazmanian SK, Skaar EP, Gaspar AH, Humayun M, Gornicki P, Jelenska J, Joachmiak A, Missiakas DM, Schneewind O (2003) Passage of heme-iron across the envelope of Staphylococcus aureus. Science 299(5608):906–909. doi:10.1126/science.1081147
15. Brown M, Kowalski R, Zorman J, Wang XM, Towne V, Zhao Q, Secore S, Finnefrock AC, Ebert T, Pancari G, Isett K, Zhang Y, Anderson AS, Montgomery D, Cope L, McNeely T (2009) Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol 16(8):1095–1104. doi:10.1128/CVI.00085-09
16. Gouaux E, Hobaugh M, Song L (1997) alpha-Hemolysin, gamma-hemolysin, and leukocidin from Staphylococcus aureus: distant in sequence but similar in structure. Protein Sci 6(12):2631–2635. doi:10.1002/pro.5560061216
17. Prevost G, Cribier B, Couppie P, Petiau P, Supersac G, Finck-Barbancon V, Monteil H, Piemont Y (1995) Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun 63(10):4121–4129
18. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, Bes M, Vandenesch F, Tazir M, Hooijkaas H, Verbrugh HA, van Belkum A, Etienne J, Lina G, Ramdani-Bouguessa N, van Wamel WJ (2010) Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis 50(1):61–68. doi:10.1086/648673
19. Sen TZ, Jernigan RL, Garnier J, Kloczkowski A (2005) GOR V server for protein secondary structure prediction. Bioinformatics 21(11):2787–2788. doi:10.1093/bioinformatics/bti408
20. Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinform 9:40. doi:10.1186/1471-2105-9-40
21. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31(13):3406–3415
22. Doytchinova IA, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform 8:4. doi:10.1186/1471-2105-8-4
23. El-Manzalawy Y, Dobbs D, Honavar V (2008) Predicting flexible length linear B-cell epitopes. Comput Syst Bioinform Life Sci Soc Comput Syst Bioinform Conf 7:121–132
24. Kringelum JV, Lundegaard C, Lund O, Nielsen M (2012) Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol 8(12):e1002829. doi:10.1371/journal.pcbi.1002829
25. Aghababa H, Mohabati Mobarez A, Khoramabadi N, Behmanesh M, Mahdavi M, Tebianian M, Nejati M (2014) A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice. Mol Biotechnol 56(6):487–497. doi:10.1007/s12033-013-9696-y
26. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A (1998) Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Investig 101(12):2640–2649. doi:10.1172/JCI1823
27. Swanson RN, O’Brien AD (1983) Genetic control of the innate resistance of mice to Salmonella typhimurium: Ity gene is expressed in vivo by 24 hours after infection. J Immunol 131(6):3014–3020
28. Sydnor ER, Perl TM (2011) Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 24(1):141–173. doi:10.1128/CMR.00027-10
29. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nunez L, Carriere M, Singer C, Dilts DA, Jansen KU (2012) Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J Infect Dis 205(11):1688–1696. doi:10.1093/infdis/jis272
30. Schaffer AC, Lee JC (2009) Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 23(1):153–171. doi:10.1016/j.idc.2008.10.005
31. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD (2008) Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198(4):571–575. doi:10.1086/590210
32. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM, Schneewind O (2010) IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28(38):6382–6392. doi:10.1016/j.vaccine.2010.02.097
33. Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Sollner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Nagy E, Meinke A (2002) Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99(10):6573–6578. doi:10.1073/pnas.092569199
34. Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, Towne V, Fan H, Wang XM, Wu X, Ernst R, Harvey BR, Finnefrock AC, Wang F, Tan C, Durr E, Cope L, Anderson A, An Z, McNeely T (2010) A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Human Antib 19(4):113–128. doi:10.3233/HAB-2010-0235
35. Josefsson E, Hartford O, O’Brien L, Patti JM, Foster T (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184(12):1572–1580. doi:10.1086/324430
36. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU (2012) Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccine Immunother 8(11):1585–1594. doi:10.4161/hv.21872
37. Gong R, Hu C, Xu H, Guo A, Chen H, Zhang G, Shi L (2010) Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice. Clin Vaccine Immunol 17(11):1746–1752. doi:10.1128/CVI.00162-10
38. Kawano Y, Fukuda J, Nasu K, Nishida M, Narahara H, Miyakawa I (2004) Production of macrophage inflammatory protein-3α in human follicular fluid and cultured granulosa cells. Fertil Steril 82(Suppl 3):1206–1211. doi:10.1016/j.fertnstert.2004.05.070
39. Naber CK (2009) Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 48(Suppl 4):S231–S237. doi:10.1086/598189
40. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB (2012) Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 25(2):362–386. doi:10.1128/CMR.05022-11